SEARCH

SEARCH BY CITATION

References

  • Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1): S1S254.
  • Ascencio C, Torres N, Isoard-Acosta F, Gómez-Pérez FJ, Hernandez-Pando R, Tovar AR (2004). Soy protein affects serum insulin and hepatic SREBP-1 mRNA and reduces fatty liver in rats. J Nutr 134: 522529.
  • Barbera MJ, Schluter A, Pedraza N, Iglesias R, Villarroya F, Giralt M (2001). Peroxisome proliferator-activated receptor alpha activates transcription of the brown fat uncoupling protein-1 gene. A link between regulation of the thermogenic and lipid oxidation pathways in the brown fat cell. J Biol Chem 276: 14861493.
  • Barros RP, Machado UF, Warner M, Gustafsson JA (2006). Muscle GLUT4 regulation by estrogen receptors ERbeta and ERalpha. Proc Natl Acad Sci U S A 103: 16051608.
  • Bathena SJ (2000). Dietary fatty acids and fatty acid metabolism in diabetes. In: Chow CK (ed.). Fatty Acids in Foods and Their Health Implications, 2nd edn. Marcel Dekker: New York, pp. 915961.
  • Bhathena SJ, Velasquez MT (2002). Beneficial role of dietary phytoestrogens in obesity and diabetes. Am J Clin Nutr 76: 11911201.
  • Cassidy A, Hooper L (2006). Phytoestrogens and cardiovascular disease. J Br Menopause Soc 12: 4956.
  • Cederroth CR, Nef S (2009). Soy, phytoestrogens and metabolism: a review. Mol Cell Endocrinol 304: 3042.
  • Cederroth CR, Vinciguerra M, Gjinovci A, Kuhne F, Klein M, Cerderroth M et al. (2008). Dietary phytoestrogens activate AMP-activated protein kinase with improvement in lipid and glucose metabolism. Diabetes 57: 11761185.
  • Clair RS, Anthony M (2005). Soy, isoflavones and atherosclerosis. Handb Exp Pharmacol 170: 301323.
  • Clarkson TB (2002). Soy, soy phytoestrogens and cardiovascular disease. J Nutr 132: 566S569S.
  • Cohen P, Ntambi JM, Friedman JM (2003). Stearoyl-CoA desaturase-1 and the metabolic syndrome. Curr Drug Targets Immune Endocr Metabol Disord 3: 271280.
  • Cooke PS, Naaz A (2004). Role of estrogens in adipocyte development and function. Exp Biol Med 229: 11271135.
  • Crespillo A, Suárez J, Bermúdez-Silva FJ, Rivera P, Vida M, Alonso M et al. (2011). Expression of cannabinoid system in muscle: effects of high fat diet and CB1 receptor blockade. Biochem J 433: 175185.
  • Dang Z, Lowik CW (2004). The balance between concurrent activation of ERs and PPARs determines daidzein-induced osteogenesis and adipogenesis. J Bone Miner Res 19: 853861.
  • Davis J, Higginbotham A, O'Connor T, Moustaid-Moussa N, Tebbe A, Kim YC et al. (2007). Soy protein and isoflavones influence adiposity and development of metabolic syndrome in obese male ZDF rat. Ann Nutr Metab 51: 4252.
  • Dobrzyn P, Dobrzyn A, Miyazaki M, Cohen P, Asilmz E, Hardie G et al. (2004). Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. Prot Natl Acad Sci U S A 101: 64096414.
  • Evans RM, Barish GD, Wang Y (2004). PPARs and the complex journey to obesity. Nat Med 10: 355361.
  • García-Serrano S, Moreno-Santos I, Garrido-Sánchez L, Gutierrez-Repiso C, García-Almeida JM, García-Arnés J et al. (2011). Stearoyl-CoA desaturase-1 is associated with insulin resistance in morbidly obese subjects. Mol Med 17: 273280.
  • Godsland IF (2005). Oestrogens and insulin secretion. Diabetologia 48: 22132220.
  • Guo Y, Wu G, Su X, Yang H, Zhang J (2009). Antiobesity action of a daidzein derivative on male obese mice induced by a high-fat diet. Nutr Res 29: 656663.
  • Harp JB (2004). New insights into inhibitors of adipogenesis. Curr Opin Lipidol 15: 303307.
  • Jiang G, Li Z, Liu F, Ellsworth K, Dallas-Yang Q, Wu M et al. (2005). Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1. J Clin Invest 115: 10301038.
  • Kim MH, Park JS, Jung JW, Byun KW, Kang KS, Lee YS (2010). Daidzein supplementation prevents non-alcoholic fatty liver disease through alternation of hepatic gene expression profiles and adipocyte metabolism. Int J Obes doi:10.1038/ijo.2010.256 [Epub ahead of print].
  • Kopelman PG (2000). Obesity as a medical problem. Nature 404: 635643.
  • Kota BP, Huang TH, Roufogalis BD (2005). An overview on biological mechanisms of PPARs. Pharmacol Res 51: 8594.
  • Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT et al. (1998). Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139: 42524263.
  • Le May C, Chu K, Hu M, Ortega CS, Simpson ER, Korach KS et al. (2006). Estrogens protects pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci U S A 103: 92329237.
  • Liu S, Mauvais-Jarvis F (2010). Estrogenic protection of beta-cell failure in metabolic diseases. Endocrinology 151: 850864.
  • Messina M, Gardner C, Barnes S (2002). Gaining insight into the health effects of soy but a long way still to go: commentary on the fourth International Symposium on the Role of Soy in Preventing and Treating Chronic Disease. J Nutr 132: 547S551S.
  • Mezei O, Banz WJ, Steger RW, Peluso MR, Winster TA, Shay N (2003). Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathway in obese Zucker rats and murine RAW 264.7 cells. J Nutr 133: 12381243.
  • Mezei O, Li Y, Mullen E, Ross-Viola JS, Shay NF (2006). Dietary isoflavone supplementation modulates lipid metabolism via PPARalpha-dependent and – independent mechanisms. Physiol Genomics 26: 814.
  • Michael MR, Wolz E, Davidovich A, Pfannkuch F, Edwards JA, Bausch J (2006). Acute, subchronic and chronic safety studies with genistein in rats. Food Chem Toxicol 44: 5680.
  • Mullen E, Brown RM, Osborne TF, Shay NF (2004). Soy isoflavones affect sterol regulatory element binding proteins (SREBPs) and SREBP regulated genes in HepG2 cells. J Nutr 34: 29422947.
  • Na XL, Ezaki J, Sugiyama F, Cui HB, Ishimi Y (2008). Isoflavone regulates lipid metabolism via expression of related genes in OVX rats fed on a high-fat. Diet 21: 357364.
  • Nagasawa A, Fukui K, Kojima M, Kishida K, Maeda N, Nagaretani H et al. (2003). Divergent effects of soy protein diet on the expression of adipocytokines. Biochem Biophys Res Commun 311: 909914.
  • Osei-Hyiaman D, DePetrilllo M, Parcher P, Liu J, Radaeva S, Bátkai S et al. (2005). Endocannabinoid activation at hepatic CB(1) receptors stimulates fatty acid synthesis and contributes to diet-induced-obesity. J Clin Invest 115: 12981305.
  • Piomelli D (2003). The molecular logic of endocannabinoid signaling. Nat Rev Neurosci 4: 873884.
  • Ronis MJ, Chen Y, Badeaux J, Badger T (2009). Dietary soy protein isolate attenuates metabolic syndrome in rats via effects on PPAR, LXR, and SREBP signaling. J Nutr 139: 14311438.
  • Rosen ED (2005). The transcriptional basis of adipocytes development. Prostaglandins Leukot Essent Fatty Acids 73: 3134.
  • Severson RK, Nomura AM, Grove JS, Stemmermann GN (1989). A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res 49: 18571860.
  • Shen P, Liu MH, Ng TY, Chan YH, Yong EL (2006). Differential effects of isoflavones, from Astragalus membranaceus and Pueraria thomsonii, on the activation of PPARalpha, PPARgamma, and adipocyte differentiation in vitro. J Nutr 136: 899905.
  • Shin ES, Lee HH, Cho SY, Park HW, Lee SJ, Lee TR (2007). Genistein downregulates SREBP-1 regulated gene expression by inhibiting Site 1 Protease expression in HepG2 cells. J Nutr 137: 11271131.
  • Shukla A, Brandsch C, Bettzieche A, Hirche F, Stangl GI, Eder K (2007). Isoflavone-poor soy protein alters the lipid metabolism of rats by SREBP-mediated down-regulation of hepatic genes. J Nutr Biochem 18: 313321.
  • Taku K, Umegaki K, Sato Y, Taki Y, Endoh K, Watanabe S (2007). Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr 85: 11481156.
  • Tham DM, Gardner CD, Haskell WL (1998). Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab 83: 22232235.
  • Vedavanam K, Srijayanta S, O'Reilly J, Raman A, Wiseman H (1999). Antioxidant action and potential antidiabetic properties of an isoflavonoid-containing soyabean phytochemical extract (SPE). Phytother Res 13: 601608.
  • Woods A, Azzout-Marniche D, Foretz M, Stein SC, Lemarchand P, Ferre P et al. (2000). Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol Cell Biol 20: 67046711.
  • Xue B, Coulter A, Rim JS, Koza RA, Kozak LP (2005). Transcriptional synergy and the regulation of Ucp1 during brown adipocyte induction in white fat depots. Mol Cell Biol 25: 83118322.
  • Zhan S, Ho SC (2005). Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am J Clin Nutr 81: 397408.
  • Zhang C, Ho SC, Lin F, Cheng S, Fu J, Chen Y (2010). Soy product and isoflavone intake and breast cancer risk defined by hormone receptor status. Cancer Sci 101: 501507.
  • Zhu BT, Han GZ, Shim JY, Wen Y, Jiang XR (2006). Quantitative structure-activity relationship (QSAR) of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: insight into the structural determinants favoring a differential subtype binding. Endocrinology 147: 41324150.
  • Zhuo XG, Melby MK, Watanabe S (2004). Soy isoflavone intake lowers serum LDL cholesterol: a meta-analysis of 8 randomized controlled trials in humans. J Nutr 134: 23952400.